InvestorsHub Logo
Followers 61
Posts 595
Boards Moderated 0
Alias Born 08/10/2014

Re: None

Monday, 11/10/2014 5:46:22 PM

Monday, November 10, 2014 5:46:22 PM

Post# of 403767
Interesting that Brilacidin is not a 'lead compound.'

Page 7

Nature of Operations

Overview

We are in the business of developing innovative small molecule therapies to treat diseases with significant medical need, particularly in the areas of cancer and inflammatory disease. Our strategy is to use our business and scientific expertise to maximize the value of our pipeline. We will do this by focusing initially on our lead compounds, Kevetrin and Prurisol and advancing them as quickly as possible along the regulatory pathway. We will develop the highest quality data and broadest intellectual property to support our compounds.